Dr. Bill Kohlbrenner Joins BioLoomics
BioLoomics is excited to welcome Dr. Bill Kohlbrenner to the team as Vice President of Business Development. Prior to joining BioLoomics, Bill has had a fruitful career ...
2021 Virtual KAND Family & Scientific Engagement Conference
Join us July 9th and 10th for the KAND Family & Scientific Engagement Conference hosted by KIF1A.ORG. Register here to join the conversation and learn about the latest ...
BioLoomics & KIF1A.ORG search for Treatments and a Cure for KAND
BioLoomics is joining KIF1A.ORG in its search for a treatment and cure for KIF1A-Associated Neurological Disorder (KAND). We are applying our evolution-in-a-microscope technology to build high throughput ...
Dr. Michael Stowell Joins Scientific Advisory Board
BioLoomics is forming a Scientific Advisory Board (SAB) to bring together diverse experts to bolster our mission to produce drug discovery assays and the first biosensing biologics with ...
BioLoomics Closed $575,000 Seed Funding Round
BioLoomics closed a $575,000 round of seed funding on May 11, 2021. The funds were contributed by private investors, including several investors who participated in the pre-seed round. ...